| Literature DB >> 24603410 |
Alexey A Moskalev1, Alexander M Aliper2, Zeljka Smit-McBride3, Anton Buzdin4, Alex Zhavoronkov5.
Abstract
Evolutionary theories of aging predict the existence of certain genes that provide selective advantage early in life with adverse effect on lifespan later in life (antagonistic pleiotropy theory) or longevity insurance genes (disposable soma theory). Indeed, the study of human and animal genetics is gradually identifying new genes that increase lifespan when overexpressed or mutated: gerontogenes. Furthermore, genetic and epigenetic mechanisms are being identified that have a positive effect on longevity. The gerontogenes are classified as lifespan regulators, mediators, effectors, housekeeping genes, genes involved in mitochondrial function, and genes regulating cellular senescence and apoptosis. In this review we demonstrate that the majority of the genes as well as genetic and epigenetic mechanisms that are involved in regulation of longevity are highly interconnected and related to stress response.Entities:
Keywords: aging; epigenetics; evolution; genetics; longevity
Mesh:
Year: 2014 PMID: 24603410 PMCID: PMC4013158 DOI: 10.4161/cc.28433
Source DB: PubMed Journal: Cell Cycle ISSN: 1551-4005 Impact factor: 4.534

Figure 1. The effect of environmental and genetic factors on aging and the formation of age-dependent diseases.

Figure 2. Stresses of various magnitudes affect aging rate and lifespan through different mechanisms.

Figure 3. Longevity genes involved in stress response. The relationship between proteins is depicted with arrows, where green and red represent activation and inhibition, respectively.

Figure 4. IGF-1-mediated signaling combined with longevity proteins that are not directly involved in stress response.
Table 1. Life extension in model organisms
| Gene | Human homolog | Organism | Wild-type lifespan | Life extension (%) | Mechanism | Gender | References |
|---|---|---|---|---|---|---|---|
| daf-2 | IGFR-1 | 14.9 ± 0.1 d | 83.0% | Gene inactivation leads to disruption of insulin signaling | N/A | ||
| age-1 | PI3K | 16 ± 2 d | ~1000% | Gene inactivation leads to disruption of insulin signaling | N/A | ||
| bec-1 | beclin | 22.4–31.1 d (mean lifespan) | −15–30% (across six trials) | Gene inactivation leads to disruption of autophagy | N/A | ||
| hsf-1 | HSF | 13.8 ± 0.5 d | 22.0% | Gene overexpression leads to activation of the heat shock promoter | N/A | ||
| daf-16 | FOXO | 23.2 ± 0.8 d | −27.0% | Gene inactivation leads to disregulation of stress response machinnery | N/A | ||
| let-363 | TOR | 10 d | 250.0% | Gene inactivation leads to disruption of insulin signaling | N/A | ||
| sgk-1 | SGK | 14.7 ± 0.3 d | 61.0% | Gene inactivation leads to disruption of insulin signaling (as sgk-1 acts in parallel with AKT kinases) and better stress response. | N/A | ||
| hcf-1 | HCFC1 | 14.3 ± 0.1 d | 28.0% | Gene inactivation leads to activation of stress response by daf-16/FOXO | N/A | ||
| jnk-1 | JNK | 16.8 ± 0.2 d | −21.7% | Gene inactivation leads to disruption of stress response by daf-16/FOXO | N/A | ||
| jkk-1 | JKK1 | 16.8 ± 0.2 d | −20.9% | Gene inactivation leads to disruption of stress response by daf-16/FOXO | N/A | ||
| akt-1 akt-2 | AKT1 AKT2 | 14.7 ± 0.3 d | 19.0% | Simultaneous inactivation of these genes leads to disruption of insulin signaling | N/A | ||
| sod1 | SOD1 | 18 d | 33% (averaged across trials 1 and 2) | Overexpression of sod1 activates longevity-promoting transcription factors. | N/A | ||
| sod2 | SOD2 | 19 d | 10% (averaged across trials 5 and 6) | Overexpression of sod2 activates longevity-promoting transcription factors. | N/A | ||
| dSir2 | SIRT1 | 37 d | 57.0% | Overexpression of dSir2 enhances energy metabolism | female | ||
| dSir2 | SIRT1 | 41 d | 32.0% | Overexpression of dSir2 enhances energy metabolism | male | ||
| chico | InRS | 44 d | 47.7% | Gene inactivation leads to disruption of insulin signaling | female | ||
| InR | InR | N/A | 85.0% | Gene inactivation leads to disruption of insulin signaling | female | ||
| dFOXO | FOXO | Varies across trials | 19.4% (averaged across trials) | Overexpression of dFOXO leads to disruption of insulin signaling | female | ||
| dFOXO | FOXO | Varies across trials | 15.5% (averaged across trials) | Overexpression of dFOXO leads to disruption of insulin signaling | male | ||
| dPTEN | PTEN | 57 d | 17.4% | Overexpression of dPTEN leads to disruption of insulin signaling | female | ||
| dPTEN | PTEN | 51 d | 19.6% | Overexpression of dPTEN leads to disruption of insulin signaling | male | ||
| hsp22 | HSP22 | 60 ± 3 d | 32.0% | Overexpression of hsp22 increases cell-protection against oxidative injuries | male | ||
| sod2 | SOD2 | 77.8 ± 5.7 d and 74.7 ± 5.1 d | −9.5% and −7.4% | Overexpression of SOD2 caused decrease of mitochondrial H2O2 release and enhancement of free methionine content essential for normal biological processes. | male | ||
| sod1 | SOD1 | 27 d | >66% | Overexpression of sod1 in motorneurons enhances RO metabolism | male | ||
| mTOR | TOR | N/A | 30.0% | Overexpression of dominant negative form of TOR alters stress responses translation and/or mitochondrial function | male | ||
| dS6K | S6K | N/A | 29.0% | Overexpression of dominant negative form of S6 kinase alters stress responses translation and/or mitochondrial function | male | ||
| IGFR-1 | IGFR-1 | 568 ± 49 d | 33.0% | Gene inactivation leads to disruption of insulin signaling | female | ||
| IGFR-1 | IGFR-1 | 585 ± 69 d | 16.0% | Gene inactivation leads to disruption of insulin signaling | male | ||
| p66shc | p66 | 761 ± 19.02 d | 30.0% | Disactivation of p66 contributes to increased cellular and organism oxidative stress resistance | male and female | ||
| Klotho | KLOTHO | 715 ± 44 d | 20.0 and 30.8% (transgenic lines EFmKL46 and EFmKL48) | Gene inactivation leads to disruption of insulin signaling | male | ||
| Klotho | KLOTHO | 697 ± 45 d | 18.8 and 19.0% (transgenic lines EFmKL46 and EFmKL48) | Gene inactivation leads to disruption of insulin signaling | female | ||
| Arf | p19 | 113.8 ± 2.4 wk | 16.0% | Hypothetically activation of Arf/p53 module provides anti-cancer and anti-aging effect detecting cellular damage. | male and female | ||
| SIRT6 | SIRT6 | 851.3 ± 24.9 and 724.0 ± 35.0 d (transgenic lines 55 and 108) | 14.8% and 16.9% (transgenic lines 55and 108) | Overexpression leads to higher levels of IGF-binding protein 1 and altered phosphorylation levels of major components of IGF1 signaling | male | ||
| p63 | p63 | 121 wk (median lifespan) | −21.5% | p63 deficiency activates widespread cellular senescence with enhanced expression of senescent markers SA-β-gal PML and p16INK4a | male and female | ||
| Brca1 | Brca | 713 ± 146 d | −8.0% | Gene inactivation leads to hypersensitivity to DNA damaging agents and consequently genomic instability of cells | female |
Table 2. Summary of the available funding and citation data.
| Process | Gene | Funding | Citations | F/C | F/TF | AF | AF/TF** | YFC | YFCA | FC-A | A-T |
|---|---|---|---|---|---|---|---|---|---|---|---|
| TP53 or P53 or Dmp53 | $4 027 210 538 | 68 834 | $58 506 | 46.97% | $195 599 425 | 4.86% | 1979 | 1987 | 32 | 8 | |
| MAPK14 | $458 530 482 | 1706 | $268 775 | 5.35% | $23 968 444 | 5.23% | 2001 | 2006 | 10 | 5 | |
| MAPK8 | $424 571 226 | 1196 | $354 993 | 4.95% | $22 578 844 | 5.32% | 2000 | 2000 | 11 | 0 | |
| SOD1 or sod-1 | $274 749 561 | 4128 | $66 558 | 3.20% | $46 503 534 | 16.93% | 1975 | 1985 | 36 | 10 | |
| SOD2 or sod-2 | $203 094 775 | 1374 | $147 813 | 2.37% | $28 305 859 | 13.94% | 1973 | 1985 | 38 | 12 | |
| CDKN1A | $131 529 936 | 10 438 | $12 601 | 1.53% | $13 032 831 | 9.91% | 1993 | 1993 | 18 | 0 | |
| SIRT1 or sir2 or dSir2 | $116 967 665 | 3052 | $38 325 | 1.36% | $101 117 219 | 86.45% | 1984 | 1999 | 27 | 15 | |
| MAPK1 or mpk1 | $103 268 829 | 11 237 | $9190 | 1.20% | $8 223 868 | 7.96% | 1982 | 1993 | 29 | 11 | |
| HDAC6 | $101 832 683 | 474 | $214 837 | 1.19% | $- | 0.00% | 1999 | 2006 | 12 | 7 | |
| MAPK9 | $32 669 688 | 252 | $129 642 | 0.38% | $368 385 | 1.13% | 1994 | - | |||
| HDAC2 | $31 533 278 | 802 | $39 318 | 0.37% | $- | 0.00% | 1997 | 2001 | 14 | 4 | |
| RXRA | $30 032 747 | 356 | $84 362 | 0.35% | $1 848 693 | 6.16% | 1992 | 2011 | 19 | 19 | |
| WNT5A | $27 790 400 | 862 | $32 239 | 0.32% | $ - | 0.00% | 1993 | 2000 | 18 | 7 | |
| GSK3 or sgg | $27 250 742 | 1372 | $19 862 | 0.32% | $2 505 572 | 9.19% | 1980 | 1995 | 31 | 15 | |
| MAPK10 | $17 683 286 | 88 | $200 946 | 0.21% | $1 216 021 | 6.88% | 1991 | - | |||
| GADD45A | $12 777 259 | 482 | $26 509 | 0.15% | $1 296 966 | 10.15% | 1995 | 1999 | 16 | 4 | |
| GADD45G | $7 537 188 | 69 | $109 235 | 0.09% | $2 062 285 | 27.36% | 1998 | 2010 | 13 | 12 | |
| FOXA3 or HNF3G or TCF3G | $5 315 519 | 119 | $44 668 | 0.06% | $ - | 0.00% | 1990 | 1999 | 21 | 9 | |
| MAPK12 | $1 438 384 | 68 | $21 153 | 0.02% | $ - | 0.00% | 1992 | - | |||
| SIRT7 | $1766 | 51 | $35 | 0.00% | $1766 | 100% | 2000 | 2005 | 11 | 5 | |
| MTOR or TOR | $821 029 426 | 23 778 | $34 529 | 9.58% | $68 845 232 | 8.39% | 1975 | 1988 | 36 | 13 | |
| PPARG | $213 853 403 | 10 059 | $21 260 | 2.49% | $15 193 855 | 7.10% | 1993 | 1994 | 18 | 1 | |
| AKT1 or akt-1 | $121 140 702 | 5408 | $22 400 | 1.41% | $7 246 805 | 5.98% | 1977 | 1999 | 34 | 22 | |
| PPARA | $74 581 825 | 750 | $99 442 | 0.87% | $1 120 366 | 1.50% | 1993 | 2002 | 18 | 9 | |
| AKT2 or akt-2 | $71 265 752 | 875 | $81 447 | 0.83% | $2 598 915 | 3.65% | 1987 | 1999 | 24 | 12 | |
| RXRA | $27 790 400 | 356 | $78 063 | 0.32% | $1 848 693 | 6.65% | 1992 | 2011 | 19 | 19 | |
| HDAC5 | $24 234 263 | 310 | $78 175 | 0.28% | $986 700 | 4.07% | 1999 | 2002 | 12 | 3 | |
| SHC1 | $16 912 072 | 898 | $18 833 | 0.20% | $1 238 936 | 7.33% | 1992 | 1997 | 19 | 5 | |
| HDAC9 | $5 844 910 | 106 | $55 141 | 0.07% | $- | 0.00% | 2001 | 2002 | 10 | 1 | |
| GSK3A | $2 120 564 | 150 | $14 137 | 0.02% | $- | 0.00% | 1995 | 2013 | 16 | 18 | |
| EIF4EBP1 or d4EBP | $608 042 | 818 | $743 | 0.01% | $- | 0.00% | 1994 | 2006 | 17 | 12 | |
| MTOR or TOR | $821 029 426 | 23 778 | $34 529 | 9.58% | $68 845 232 | 8.39% | 1975 | 1988 | 36 | 13 | |
| AKT1 or akt-1 | $121 140 702 | 5408 | $22 400 | 1.41% | $7 246 805 | 5.98% | 1977 | 1999 | 34 | 22 | |
| MAPK1 | $96 943 128 | 11 067 | $8 760 | 1.13% | $8 223 868 | 8.48% | 1991 | 1993 | 20 | 2 | |
| EIF4E | $69 771 228 | 2392 | $29 169 | 0.81% | $3 935 384 | 5.64% | 1991 | 2001 | 20 | 10 | |
| PTK2B | $44 532 289 | 298 | $149 437 | 0.52% | $- | 0.00% | 1995 | 2010 | 16 | 15 | |
| EIF4G1 or EIF4G | $3 998 998 | 970 | $4123 | 0.05% | $911 650 | 22.80% | 1995 | 2001 | 16 | 6 | |
| EIF4EBP1 or d4EBP | $608 042 | 818 | $743 | 0.01% | $- | 0.00% | 1994 | 2006 | 17 | 12 | |
| Total |
F/C, funding per citation; F/TF, funding for a specific gene as percentage of total funding; AF, funding for projects with the specific gene name and “aging” in the grant application; YFC, year of first citation; YFCA, year of first citation with “aging” in the abstract; FC-A, the time between first citation of the gene and citation with “aging”; A-T, the time between 2013 and the time of the first citation of the gene with “aging” in the abstract.